CHARLOTTE, N.C., Nov. 24, 2025 — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8 and a global health-tech and longevity firm known for its dual strategy in consumer wellness and Bitcoin, announced today that all key members of its executive leadership team have conducted open market purchases of Prenetics’ common stock during the Company’s designated trading window.
Collectively, the executive team acquired 111,911 shares of Prenetics’ common stock for a total purchase price of approximately $1,446,887.
Individual Transaction Details
Danny Yeung, Chief Executive Officer
In two open market transactions on November 18 and 19, Mr. Yeung purchased a total of 40,118 shares for an approximate total of $502,000, at an average price of about $12.51 per share.
Rahul Ramchand, Chief Marketing Officer
In two open market transactions on November 12 and 14, Mr. Ramchand acquired a total of 60,000 shares for an approximate total of $793,972, at an average price of about $13.23 per share.
Stephen Lo, Chief Financial Officer
In an open market transaction on November 21, Mr. Lo acquired 8,000 shares for an approximate total of $100,915, at an average purchase price of about $12.61 per share.
David Vanderveen, President of Americas
In an open market transaction on November 20, Mr. Vanderveen purchased 3,793 shares for an approximate total of $50,000, at an average purchase price of about $13.15 per share.
Prenetics CEO, Danny Yeung, remarked:
“These purchases reflect our collective conviction in the long-term vision of Prenetics and IM8. With IM8 scaling rapidly as one of the fastest-growing wellness brands globally and our Bitcoin-treasury strategy reinforcing long-term financial resilience, our executive team is fully aligned with shareholders. We believe Prenetics is still in the early innings of unlocking its true value, and we are investing personally because we see an exceptional future ahead.”
This press release will be furnished as an exhibit to a Form 6-K that will be filed with the U.S. Securities and Exchange Commission.
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company redefining the future of health and longevity through IM8 — its flagship consumer brand co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka. IM8 has achieved the fastest growth trajectory in supplement industry history, reaching $100M Annual Recurring Revenue in just 11 months from launch, outpacing even leading AI startups.
As the first consumer health company to establish a Bitcoin treasury, Prenetics continues to pioneer at the intersection of health innovation and digital assets – purchasing 1 Bitcoin per day, now totaling 501 BTC as of November 24, 2025.
About IM8
IM8 represents the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.
Investor Relations Contact:
Angela Cheung
Investor Relations / Corporate Finance
Forward-Looking Statements
This press release includes forward-looking statements. Such statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements encompass any statements that are not historical facts, including those concerning the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, management objectives for future operations, and growth opportunities. Management’s current estimates and assumptions as of the date of this release inform our guidance, which is subject to substantial risks and uncertainties and does not guarantee future performance. Actual outcomes could vary significantly. Forward-looking statements can sometimes be identified by terms such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other comparable expressions. Based on estimates and forecasts, forward-looking statements embody the Company’s views, assumptions, expectations, and opinions. These statements involve inherent risks and uncertainties and thus should not be taken as necessarily indicative of future results. Numerous factors could lead to actual results differing materially from those in any forward-looking statement. These include, but are not limited to: potential additional risks from future alpha-generating activities involving the Company’s Bitcoin holdings; exposure to risks associated with Bitcoin’s extreme volatility and speculative nature due to the Company’s Bitcoin purchases; potential inability to sustain and grow the IM8 business and brand if negative publicity occurs, if a strong base of engaged customers and content creators is not maintained, or if customer expectations are not met; the Company’s capacity to further develop and expand its business, including new products and services; its ability to implement its new business strategy in genomics, precision oncology, and particularly, early cancer detection; the outcomes of case control studies and/or clinical trials; and its capability to identify and pursue M&A opportunities. Beyond these factors, investors should also thoroughly review the other risks and uncertainties detailed in the “Risk Factors” section of the Company’s latest registration statement and its prospectus, as well as other documents the Company periodically files with the U.S. Securities and Exchange Commission. Unless otherwise stated, all information contained in this press release is current as of its publication date, and the Company disclaims any obligation to update such information, except where mandated by applicable law.
